Cirrhosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
===Prevalence=== | ===Prevalence=== | ||
* In 2015, the prevalence of cirrhosis is approximately 270 per 100,000 individuals in the United States. | * In 2015, the [[prevalence]] of cirrhosis is approximately 270 per 100,000 individuals in the United States. | ||
*Currently, approximately seventy percent of cirrhotic individuals are unaware of having [[liver]] disease and go undiagnosed. | *Currently, approximately seventy percent of cirrhotic individuals are unaware of having [[liver]] disease and go undiagnosed. | ||
*The prevalence of cirrhosis is higher in: | *The [[prevalence]] of cirrhosis is higher in: | ||
**Non-Hispanic blacks | **Non-Hispanic blacks | ||
**Individuals below the poverty line | **Individuals below the poverty line | ||
| Line 20: | Line 20: | ||
**Areas with high illiteracy rates | **Areas with high illiteracy rates | ||
*[[Hepatitis|Viral hepatitis]] (mainly [[hepatitis C]]) is responsible for more than half of the cases of cirrhosis in the United States. | *[[Hepatitis|Viral hepatitis]] (mainly [[hepatitis C]]) is responsible for more than half of the cases of cirrhosis in the United States. | ||
*The cost of cirrhosis in terms of human suffering, hospital costs, and lost [[productivity]] is high. | *The cost of [[cirrhosis]] in terms of human suffering, hospital costs, and lost [[productivity]] is high. | ||
*The rate of developing [[hepatocellular carcinoma]] in cirrhotic patients is approximately 1%-4% per year.<ref name=":0">{{cite journal |author=Yu ML, Chuang WL |title=Treatment of chronic hepatitis C in Asia: when East meets West |journal=J. Gastroenterol. Hepatol. |volume=24 |issue=3 |pages=336–45 |year=2009 |pmid=19335784 |doi=10.1111/j.1440-1746.2009.05789.x |url=}},</ref> | |||
* '''Alcoholic cirrhosis:''' | * '''Alcoholic cirrhosis:''' | ||
** Alcoholic cirrhosis develops in 15% of individuals who drink heavily for more than a decade. | ** [[Cirrhosis|Alcoholic cirrhosis]] develops in 15% of individuals who drink heavily for more than a decade. | ||
** There is great variability in the amount of [[alcohol]] needed to cause cirrhosis (as little as 3-4 drinks a day in some men and 2-3 in some women). | ** There is great variability in the amount of [[alcohol]] needed to cause cirrhosis (as little as 3-4 drinks a day in some men and 2-3 in some women). | ||
* '''Chronic hepatitis B:''' | * '''Chronic hepatitis B:''' | ||
** most common cause of cirrhosis worldwide, especially South-East Asia, but is less common in the United States. | ** Chronic [[hepatitis B]] is the most common cause of cirrhosis worldwide, especially South-East Asia, but is less common in the United States. | ||
* '''Primary biliary cirrhosis:''' | * '''Primary biliary cirrhosis:''' | ||
** In some areas of the US and UK, the prevalence is as high as 1 in 4000. | ** In some areas of the US and UK, the [[prevalence]] is as high as 1 in 4000. | ||
* '''Non alcoholic fatty liver disease:''' <ref>Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132–8.</ref><ref>Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease:a clinical histopathological study. Am J Gastroenterol 2003;98(9):2042–7.</ref><ref>Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.</ref> | * '''Non alcoholic fatty liver disease:''' <ref>Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132–8.</ref><ref>Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease:a clinical histopathological study. Am J Gastroenterol 2003;98(9):2042–7.</ref><ref>Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.</ref> | ||
** [[Non-alcoholic fatty liver disease|NAFLD]] has a 30 percent risk of [[fibrosis]] | ** [[Non-alcoholic fatty liver disease|NAFLD]] has a 30 percent risk of [[fibrosis]] | ||
** [[Non-alcoholic fatty liver disease|NAFLD]] has a 2-15% rate of cirrhosis in less than 6 years | ** [[Non-alcoholic fatty liver disease|NAFLD]] has a 2-15% rate of cirrhosis in less than 6 years | ||
* '''[[Alpha 1-antitrypsin deficiency]]''': | * '''[[Alpha 1-antitrypsin deficiency]]''': | ||
** | ** Approximately 40 percent of adults with [[Zygosity|homozygosity]] of PIZZ have histologically significant [[liver]] injury and cirrhosis <ref>{{cite journal |author=Bals R |title=Alpha-1-antitrypsin deficiency |journal=Best Pract Res Clin Gastroenterol |volume=24 |issue=5 |pages=629–33 |year=2010 |pmid=20955965 |doi=10.1016/j.bpg.2010.08.006 |url=}}</ref> | ||
* [[Hepatopulmonary syndrome|Hepatopulmonary syndrom]]<nowiki/>e: | * [[Hepatopulmonary syndrome|Hepatopulmonary syndrom]]<nowiki/>e: | ||
** [[Hepatopulmonary syndrome]] has a prevalence of 4-47% in cirrhotic patients. | ** [[Hepatopulmonary syndrome]] has a prevalence of 4-47% in cirrhotic patients. | ||
| Line 40: | Line 41: | ||
** The prevalence of cirrhotic [[cardiomyopathy]] is 50% in cirrhotic patients. | ** The prevalence of cirrhotic [[cardiomyopathy]] is 50% in cirrhotic patients. | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*The 10 year-mortality rate of cirrhosis is approximately 34- 66 percent, largely dependent on the cause of cirrhosis. | *The 10 year-[[mortality rate]] of cirrhosis is approximately 34- 66 percent, largely dependent on the cause of cirrhosis. | ||
* In 2001, cirrhosis was the tenth leading cause of death amongst men and the twelfth leading cause of death amongst women in the United States.<ref>Anderson RN, Smith BL. Deaths: leading causes for 2001. ''Natl Vital Stat Rep''2003;52:1-85. PMID 14626726.</ref> | * In 2001, cirrhosis was the tenth leading cause of death amongst men and the twelfth leading cause of death amongst women in the United States.<ref>Anderson RN, Smith BL. Deaths: leading causes for 2001. ''Natl Vital Stat Rep''2003;52:1-85. PMID 14626726.</ref> | ||
| Line 50: | Line 51: | ||
*[Chronic disease name] is usually first diagnosed among [age group]. | *[Chronic disease name] is usually first diagnosed among [age group]. | ||
*[Acute disease name] commonly affects [age group]. | *[Acute disease name] commonly affects [age group]. | ||
*Cirrhosis is infrequently seen in young adults. | |||
===Race=== | ===Race=== | ||
* | *The [[prevalence]] of cirrhosis is higher in: [http://www.natap.org/2005/AASLD/aasld_29.htm] | ||
* | **Non-Hispanic blacks | ||
**Individuals below the poverty line | |||
**Mexican Americans | |||
**Areas with high illiteracy rates | |||
**Hispanics with [[hepatitis C]] infection | |||
===Gender=== | ===Gender=== | ||
*[ | *The gender that is most commonly affected by cirrhosis varies, depending on the underlying [[etiology]]. | ||
*[ | *'''Primary biliary cirrhosis''': | ||
=== | **[[Primary biliary cirrhosis]] is more common in women. | ||
* | * '''Chronic [[Hepatitis C]]''': | ||
** The risk of cirrhosis after 20 years is estimated to be approximately 10%-15% for men and 1-5% for women.<ref name=":0" /> | |||
*[ | * '''Non alcoholic fatty liver disease''': | ||
** [[Non-alcoholic fatty liver disease]] is more common among men than women in all age groups until age 60. | |||
** At 60 years of age, the prevalence of cirrhosis in males and females equalizes, due to absence of the protective nature of [[estrogen]].<ref name="Lobanova2009">{{cite journal|author=Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA, Krasil’nikov MA|title=NF- kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis|journal=Mol Cell Biochem|volume=324|year=2009}}</ref> | |||
* '''Autoimmune hepatitis''': | |||
** [[Autoimmune hepatitis]] usually occurs in women in seventy percent of cases between the ages of 15 and 40. | |||
* '''[[Alpha1 antitrypsin deficiency]]''': | |||
** Male gender and [[obesity]] may be risk factors for progression to advanced [[liver]] disease in adulthood among patients with severe [[Alpha 1-antitrypsin deficiency|AAT]] deficiency.<ref>{{cite journal |author=Bowlus CL, Willner I, Zern MA, ''et al.'' |title=Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency |journal=Clin. Gastroenterol. Hepatol. |volume=3 |issue=4 |pages=390–6 |year=2005 |pmid=15822045 |doi= |url=}}</ref> | |||
===Developed Countries=== | ===Developed Countries=== | ||
* [[Hepatitis|Viral hepatitis]] (mainly [[hepatitis C]]) is responsible for more than half of the cases of cirrhosis in the United States. | |||
===Developing Countries=== | ===Developing Countries=== | ||
* Chronic [[hepatitis B]] is the most common cause of cirrhosis worldwide, especially South-East Asia, but is less common in the United States. | |||
* | |||
==References== | ==References== | ||
Revision as of 19:35, 18 December 2017
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cirrhosis epidemiology and demographics |
|
Risk calculators and risk factors for Cirrhosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
The most common cause of cirrhosis in the United States is chronic and heavy alcohol use, while the most common cause of cirrhosis worldwide is the hepatitis virus. Cirrhosis and chronic liver disease is the 12th leading cause of death in United States.
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- In 2015, the prevalence of cirrhosis is approximately 270 per 100,000 individuals in the United States.
- Currently, approximately seventy percent of cirrhotic individuals are unaware of having liver disease and go undiagnosed.
- The prevalence of cirrhosis is higher in:
- Non-Hispanic blacks
- Individuals below the poverty line
- Mexican Americans
- Areas with high illiteracy rates
- Viral hepatitis (mainly hepatitis C) is responsible for more than half of the cases of cirrhosis in the United States.
- The cost of cirrhosis in terms of human suffering, hospital costs, and lost productivity is high.
- The rate of developing hepatocellular carcinoma in cirrhotic patients is approximately 1%-4% per year.[1]
- Alcoholic cirrhosis:
- Alcoholic cirrhosis develops in 15% of individuals who drink heavily for more than a decade.
- There is great variability in the amount of alcohol needed to cause cirrhosis (as little as 3-4 drinks a day in some men and 2-3 in some women).
- Chronic hepatitis B:
- Chronic hepatitis B is the most common cause of cirrhosis worldwide, especially South-East Asia, but is less common in the United States.
- Primary biliary cirrhosis:
- In some areas of the US and UK, the prevalence is as high as 1 in 4000.
- Non alcoholic fatty liver disease: [2][3][4]
- Alpha 1-antitrypsin deficiency:
- Approximately 40 percent of adults with homozygosity of PIZZ have histologically significant liver injury and cirrhosis [5]
- Hepatopulmonary syndrome:
- Hepatopulmonary syndrome has a prevalence of 4-47% in cirrhotic patients.
- Portopulmonary hypertension:
- The prevalence of portopulmonary hypertension is 2% in patients with cirrhosis.
- Cirrhotic cardiomyopathy:
- The prevalence of cirrhotic cardiomyopathy is 50% in cirrhotic patients.
Case-fatality rate/Mortality rate
- The 10 year-mortality rate of cirrhosis is approximately 34- 66 percent, largely dependent on the cause of cirrhosis.
- In 2001, cirrhosis was the tenth leading cause of death amongst men and the twelfth leading cause of death amongst women in the United States.[6]
- In 2006, cirrhosis was the twelfth leading cause of all deaths in United States.[7]
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
- Cirrhosis is infrequently seen in young adults.
Race
- The prevalence of cirrhosis is higher in: [3]
- Non-Hispanic blacks
- Individuals below the poverty line
- Mexican Americans
- Areas with high illiteracy rates
- Hispanics with hepatitis C infection
Gender
- The gender that is most commonly affected by cirrhosis varies, depending on the underlying etiology.
- Primary biliary cirrhosis:
- Primary biliary cirrhosis is more common in women.
- Chronic Hepatitis C:
- The risk of cirrhosis after 20 years is estimated to be approximately 10%-15% for men and 1-5% for women.[1]
- Non alcoholic fatty liver disease:
- Non-alcoholic fatty liver disease is more common among men than women in all age groups until age 60.
- At 60 years of age, the prevalence of cirrhosis in males and females equalizes, due to absence of the protective nature of estrogen.[8]
- Autoimmune hepatitis:
- Autoimmune hepatitis usually occurs in women in seventy percent of cases between the ages of 15 and 40.
- Alpha1 antitrypsin deficiency:
Developed Countries
- Viral hepatitis (mainly hepatitis C) is responsible for more than half of the cases of cirrhosis in the United States.
Developing Countries
- Chronic hepatitis B is the most common cause of cirrhosis worldwide, especially South-East Asia, but is less common in the United States.
References
- ↑ 1.0 1.1 Yu ML, Chuang WL (2009). "Treatment of chronic hepatitis C in Asia: when East meets West". J. Gastroenterol. Hepatol. 24 (3): 336–45. doi:10.1111/j.1440-1746.2009.05789.x. PMID 19335784.,
- ↑ Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132–8.
- ↑ Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease:a clinical histopathological study. Am J Gastroenterol 2003;98(9):2042–7.
- ↑ Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
- ↑ Bals R (2010). "Alpha-1-antitrypsin deficiency". Best Pract Res Clin Gastroenterol. 24 (5): 629–33. doi:10.1016/j.bpg.2010.08.006. PMID 20955965.
- ↑ Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep2003;52:1-85. PMID 14626726.
- ↑ Heron MP, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. Deaths: Final data for 2006. National vital statistics reports; vol 57 no 14. Hyattsville, MD: National Center for Health Statistics. 2009.
- ↑ Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA, Krasil’nikov MA (2009). "NF- kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis". Mol Cell Biochem. 324.
- ↑ Bowlus CL, Willner I, Zern MA; et al. (2005). "Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency". Clin. Gastroenterol. Hepatol. 3 (4): 390–6. PMID 15822045.